Civil rights activists have gathered outside Target's Minneapolis headquarters to call for a boycott of the retailing giant ...

Target and the Target Foundation have made big gifts to groups working on Black economic empowerment and LGBTQ+ acceptance.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

StockNews.com upgraded shares of Xerox (NYSE:XRX – Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning. Several other research analysts also recently commented on XRX ...

Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Barclays analyst Brandt Montour lowered the firm’s price target on Las Vegas Sands (LVS) to $58 from $61 and keeps an Overweight rating on the ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

A FORMER substation in the Workington area could be converted into an accessible swimming pool with associated facilities if the plans are approved. The planning application, which has been lodged ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares. The company provided a “robust defense” of its Q4 ...

On Wednesday, Wells Fargo (NYSE:WFC) reiterated its Overweight rating and $1,000.00 price target on Eli Lilly (NYSE:NYSE:LLY) shares despite the pharmaceutical company's fourth-quarter revenue falling ...